Interleukin 4 and Cancer Resistance in Glioblastoma Multiforme

Overview

Journal Neurosurg Rev

Specialty Neurosurgery

Date 2024 Aug 20

PMID 39164434

Authors

Donald Detchou

Umaru Barrie

Affiliations

Soon will be listed here.

Abstract

In this review, the author highlights the role of IL4 in mitigating all the "hallmarks" of cancer growth and resistance to current immunotherapy, providing a framework for its role in GBM as well as guideline for future treatment regimens. This review is organized around six strategies by which IL4 contributes to the immune resistance seen in GBM: (i) apoptosis evasion, (ii) self-sufficiency in growth signals, (iii) insensitivity to anti-growth signals, (iv) invasion and metastasis, (v) limitless replicative potential, (vi) sustained angiogenesis.

References

Dunn G, Old L, Schreiber R . The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-60. DOI: 10.1146/annurev.immunol.22.012703.104803. View

Jackson C, Choi J, Lim M . Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019; 20(9):1100-1109. DOI: 10.1038/s41590-019-0433-y. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Weller M, Butowski N, Tran D, Recht L, Lim M, Hirte H . Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017; 18(10):1373-1385. DOI: 10.1016/S1470-2045(17)30517-X. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Koshy M, Villano J, Dolecek T, Howard A, Mahmood U, Chmura S . Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2011; 107(1):207-12. PMC: 4077033. DOI: 10.1007/s11060-011-0738-7. View

Nelms K, Keegan A, Zamorano J, Ryan J, Paul W . The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999; 17:701-38. DOI: 10.1146/annurev.immunol.17.1.701. View

Jiang H, Harris M, Rothman P . IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000; 105(6 Pt 1):1063-70. DOI: 10.1067/mai.2000.107604. View

Scheurer M, Amirian E, Cao Y, Gilbert M, Aldape K, Kornguth D . Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res. 2008; 14(20):6640-6. PMC: 2995250. DOI: 10.1158/1078-0432.CCR-07-4681. View

10.

Eisele G, Weller M . Targeting apoptosis pathways in glioblastoma. Cancer Lett. 2011; 332(2):335-45. DOI: 10.1016/j.canlet.2010.12.012. View

11.

Kruse J, Gu W . Modes of p53 regulation. Cell. 2009; 137(4):609-22. PMC: 3737742. DOI: 10.1016/j.cell.2009.04.050. View

12.

Farnebo M, Bykov V, Wiman K . The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010; 396(1):85-9. DOI: 10.1016/j.bbrc.2010.02.152. View

13.

Leonard W, Oshea J . Jaks and STATs: biological implications. Annu Rev Immunol. 1998; 16:293-322. DOI: 10.1146/annurev.immunol.16.1.293. View

14.

Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu Z . Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science. 1994; 266(5187):1045-7. DOI: 10.1126/science.7973659. View

15.

Rahaman S, Sharma P, Harbor P, Aman M, Vogelbaum M, Haque S . IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 2002; 62(4):1103-9. View

16.

Rahaman S, Harbor P, Chernova O, Barnett G, Vogelbaum M, Haque S . Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002; 21(55):8404-13. DOI: 10.1038/sj.onc.1206047. View

17.

Niu G, Wright K, Huang M, Song L, Haura E, Turkson J . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. DOI: 10.1038/sj.onc.1205260. View

18.

Cheng F, Wang H, Cuenca A, Huang M, Ghansah T, Brayer J . A critical role for Stat3 signaling in immune tolerance. Immunity. 2003; 19(3):425-36. DOI: 10.1016/s1074-7613(03)00232-2. View

19.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S . Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004; 10(1):48-54. DOI: 10.1038/nm976. View

20.

Yu H, Jove R . The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004; 4(2):97-105. DOI: 10.1038/nrc1275. View